<DOC>
	<DOCNO>NCT00072124</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , dacarbazine cisplatin , work different way stop tumor cell divide stop grow die . Complete metastasectomy may effective treatment metastatic melanoma may improve quality life help patient live long comfortably . It yet know whether complete metastasectomy effective chemotherapy treat stage IV melanoma . PURPOSE : This randomized phase III trial study dacarbazine and/or cisplatin see well work compare complete metastasectomy treat patient stage IV melanoma .</brief_summary>
	<brief_title>Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy Treating Patients With Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare overall survival patient stage IV melanoma treat complete metastasectomy v dacarbazine and/or cisplatin . Secondary - Compare time progression patient treat regimen . - Determine response rate patient treat dacarbazine and/or cisplatin . - Compare morbidity quality life patient treat regimen . OUTLINE : This randomize study . Patients stratify accord prior exposure dacarbazine cisplatin ( yes v ) number sit metastasis ( 1 vs 2 ) . Patients randomize 1 2 treatment arm . - Arm I ( surgery ) : Patients undergo complete metastasectomy . Patients disease progression surgery may undergo repeat resection may receive dacarbazine and/or cisplatin arm II . - Arm II ( systemic therapy ) : Patients receive dacarbazine IV 30-60 minute and/or cisplatin IV 30 minute day 1 , 2 , 3 , 22 , 23 , 24 ( 1 course ) . Courses repeat every 42 day absence disease progression unacceptable toxicity . Patients achieve complete response ( CR ) receive least 1 additional course chemotherapy beyond CR eligible investigational strategy . Quality life assess baseline , 3 6 month , 1 year . Patients follow every 3-4 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 74 patient ( 37 per treatment arm ) accrue study within 4 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis metastatic melanoma Solitary pulmonary nodule may sole site metastatic disease No disease limit subcutaneous , cutaneous , peripheral nodal ( neck , axillary , groin , iliac node ) sit Measurable disease Disease progression prior interleukin2 ( IL2 ) base therapy OR ineligible highdose IL2 therapy Metastatic disease amenable complete surgical resection Less 5 % estimate mortality surgery Prior complete metastasectomy allow provided disease recur within 6 month surgery No primary ocular mucosal melanoma No brain metastases PATIENT CHARACTERISTICS : Age 16 Performance status ECOG 02 Life expectancy More 3 month Hematopoietic WBC least 3,000/mm^3 OR Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 No coagulation disorder Hepatic Hepatitis B surface antigen negative Hepatitis C antibody negative Renal Creatinine great 1.6 mg/dL OR Creatinine clearance least 70 mL/min No major medical illness renal system Cardiovascular No major medical illness cardiovascular system Pulmonary No major medical illness respiratory system Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No active systemic infection No form primary secondary immunodeficiency PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy No concurrent palliative radiotherapy Surgery See Disease Characteristics No concurrent palliative surgery Other More 3 week since prior therapy melanoma ( except surgery ) No concurrent therapy melanoma</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2005</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>